View in EDS HTML Full Text PDF Full Text

Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.

Saved in:
Bibliographic Details
Title: Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.
Authors: Boustani M; Division of Internal Medicine and Geriatrics, Indiana University School of Medicine, Indianapolis, IN, USA., Doty EG; Lilly Corporate Center, Indianapolis, IN, 46285, USA., Garrison LP Jr; Department of Pharmacy, The CHOICE Institute, University of Washington, Seattle, WA, USA., Smolen LJ; Medical Decision Modeling Inc, Indianapolis, IN, USA., Klein TM; Medical Decision Modeling Inc, Indianapolis, IN, USA., Murphy DR; Medical Decision Modeling Inc, Indianapolis, IN, USA., Spargo AW; Lilly Corporate Center, Indianapolis, IN, 46285, USA., Belger M; Eli Lilly and Company, Bracknell, UK., Johnston JA; Lilly Corporate Center, Indianapolis, IN, 46285, USA. johnston_joseph_a@lilly.com.
Source: Neurology and therapy [Neurol Ther] 2024 Dec; Vol. 13 (6), pp. 1641-1659. Date of Electronic Publication: 2024 Sep 18.
Publication Type: Journal Article
Journal Info: Publisher: Springer Country of Publication: New Zealand NLM ID: 101637818 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8253 (Print) Linking ISSN: 21936536 NLM ISO Abbreviation: Neurol Ther Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39292433
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Boustani+M%22">Boustani M</searchLink>; Division of Internal Medicine and Geriatrics, Indiana University School of Medicine, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Doty+EG%22">Doty EG</searchLink>; Lilly Corporate Center, Indianapolis, IN, 46285, USA.<br /><searchLink fieldCode="AU" term="%22Garrison+LP+Jr%22">Garrison LP Jr</searchLink>; Department of Pharmacy, The CHOICE Institute, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Smolen+LJ%22">Smolen LJ</searchLink>; Medical Decision Modeling Inc, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Klein+TM%22">Klein TM</searchLink>; Medical Decision Modeling Inc, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Murphy+DR%22">Murphy DR</searchLink>; Medical Decision Modeling Inc, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Spargo+AW%22">Spargo AW</searchLink>; Lilly Corporate Center, Indianapolis, IN, 46285, USA.<br /><searchLink fieldCode="AU" term="%22Belger+M%22">Belger M</searchLink>; Eli Lilly and Company, Bracknell, UK.<br /><searchLink fieldCode="AU" term="%22Johnston+JA%22">Johnston JA</searchLink>; Lilly Corporate Center, Indianapolis, IN, 46285, USA. johnston_joseph_a@lilly.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101637818%22">Neurology and therapy</searchLink> [Neurol Ther] 2024 Dec; Vol. 13 (6), pp. 1641-1659. <i>Date of Electronic Publication: </i>2024 Sep 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>101637818 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2193-8253 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221936536%22">21936536 </searchLink><i>NLM ISO Abbreviation: </i>Neurol Ther <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39292433
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40120-024-00649-y
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1641
    Titles:
      – TitleFull: Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Boustani M
      – PersonEntity:
          Name:
            NameFull: Doty EG
      – PersonEntity:
          Name:
            NameFull: Garrison LP Jr
      – PersonEntity:
          Name:
            NameFull: Smolen LJ
      – PersonEntity:
          Name:
            NameFull: Klein TM
      – PersonEntity:
          Name:
            NameFull: Murphy DR
      – PersonEntity:
          Name:
            NameFull: Spargo AW
      – PersonEntity:
          Name:
            NameFull: Belger M
      – PersonEntity:
          Name:
            NameFull: Johnston JA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2024 Dec
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 2193-8253
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Neurology and therapy
              Type: main
ResultId 1